Equities analysts expect Apellis Pharmaceuticals Inc (NASDAQ:APLS) to announce earnings of ($0.65) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Apellis Pharmaceuticals’ earnings. Apellis Pharmaceuticals posted earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 8.3%. The business is scheduled to announce its next quarterly earnings report on Monday, March 18th.
On average, analysts expect that Apellis Pharmaceuticals will report full-year earnings of ($2.38) per share for the current fiscal year, with EPS estimates ranging from ($2.41) to ($2.35). For the next fiscal year, analysts forecast that the business will report earnings of ($3.05) per share, with EPS estimates ranging from ($3.24) to ($2.85). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Apellis Pharmaceuticals.
Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05.
NASDAQ APLS opened at $16.31 on Friday. The stock has a market capitalization of $954.44 million and a PE ratio of -4.44. Apellis Pharmaceuticals has a 1-year low of $11.45 and a 1-year high of $32.00. The company has a current ratio of 14.90, a quick ratio of 14.91 and a debt-to-equity ratio of 0.14.
In other news, major shareholder Morningside Venture Investment acquired 81,323 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, September 21st. The shares were acquired at an average cost of $19.48 per share, with a total value of $1,584,172.04. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 9.30% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Hillhouse Capital Management Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 203.0% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 4,328,289 shares of the company’s stock valued at $95,222,000 after buying an additional 2,899,718 shares during the period. venBio Partners L.P. purchased a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter valued at about $72,482,000. BlackRock Inc. raised its holdings in shares of Apellis Pharmaceuticals by 1.9% during the 3rd quarter. BlackRock Inc. now owns 2,853,195 shares of the company’s stock valued at $50,730,000 after buying an additional 54,227 shares during the period. Vanguard Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,414,900 shares of the company’s stock valued at $25,157,000 after buying an additional 72,610 shares during the period. Finally, Vanguard Group Inc raised its holdings in shares of Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc now owns 1,414,900 shares of the company’s stock valued at $25,157,000 after buying an additional 72,610 shares during the period. Institutional investors and hedge funds own 55.94% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Featured Article: Why do companies issue stock splits?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.